FDA Extends Review Period of REGN's Submission for Eylea HD
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
EYLEA HD® ( aflibercept ) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
TARRYTOWN, N.Y., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ( aflibercept ) Injection 8 mg regulatory ...
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening diseases The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at ...
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Brandon Hall Group™ Announces 2025 HCM Excellence Awards® Winners in Live Broadcast
Boca Raton, FL, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Brandon Hall Group™, the leading HCM research and analyst firm, today announced the winners of its 2025 HCM Excellence Awards® during a special live broadcast.
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Looking into the current session, Regeneron Pharmaceuticals Inc. REGN shares are trading at $565.50, after a 0.44% spike. Moreover, over the past month, the stock increased by 3.20%, but in the past year, decreased by 51.18%.
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
How Do Investors Really Feel About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals's REGN short percent of float has fallen 7.73% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 2.03% of all regular shares that are available for trading.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia ( NTLA ) Q2 Revenue Jumps 106%
Intellia Therapeutics ( NASDAQ:NTLA ) , a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a significant increase in collaboration revenue to $14.2 million ( GAAP ) for Q2 2025, which beat the ...
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ ( linvoseltamab-gcpt )
LOUISVILLE, Ky., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ ( linvoseltamab-gcpt ) , which has been has granted accelerated approval by the Food ...
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings - Regeneron Pharmaceuticals ( NASDAQ:REGN )
On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings. The company posted adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of ...
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals's REGN short percent of float has fallen 7.73% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 2.03% of all regular shares that are available for trading.
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT ( 2:00 p.m. CEST ...
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
These biotech businesses look compelling for very different reasons.
Smart Money Is Betting Big In REGN Options - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday? - Apple ( NASDAQ:AAPL )
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close. SPY ETF is breaking past support. Check the chart here.
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D-150 showed +9.7 letter BCVA gain and 78% fewer injections vs. standard aflibercept in DME. No intraocular inflammation or serious adverse events reported through 60 weeks. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Why Is Regeneron Stock Soaring Friday? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Q2 EPS rose 12% to $12.89, missing estimates; revenue grew 4% to $3.68 billion, beating forecasts. Eylea U.S. sales fell 25% to $1.15 billion, while Sanofi antibody profits rose to $1.28 billion on Dupixent growth. Get special access to three exclusive "Top 10 Stocks" power lists ...
Regeneron Reports Second Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the second quarter of 2025 and provided a business update.
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Regeneron Pharmaceuticals, Inc. REGN will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1. Analysts expect the Tarrytown, New York -based company to report quarterly earnings at $8.43 per share, down from $11.56 per share in the year-ago period.
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
- ARCALYST® ( rilonacept ) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated.
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Wall Street might be underestimating these companies' potential.
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 13.72% on an annualized basis producing an average annual return of 22.23%. Currently, Regeneron Pharmaceuticals has a market capitalization of $60.80 billion.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
TARRYTOWN, N.Y., July 24, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation ( the "Regeneron Prize" ) , which recognizes and rewards outstanding creativity and talent among ...
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca ( NASDAQ:AZN )
AstraZeneca plans $50 billion in U.S. investment by 2030, including a drug facility in Virginia for its metabolic and weight loss portfolio. Company aims to generate 50% of $80 billion revenue from the U.S. by 2030 with new manufacturing and R&D expansions.
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
San Francisco, USA, July 22, 2025 ( GLOBE NEWSWIRE ) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate ( CAGR ) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032.
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen ( NASDAQ:BIIB )
Biogen to invest $2 billion more in its RTP manufacturing, adding to $10B already spent in North Carolina. Expansion includes advanced automation, AI integration and multi-platform fill finish capabilities.
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals's REGN short percent of float has risen 11.11% since its last report. The company recently reported that it has 2.25 million shares sold short, which is 2.2% of all regular shares that are available for trading.
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
2 Beaten-Down Stocks to Buy and Hold
Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy. Regardless of what happens over the next six months, it's still worth it to invest in companies that look likely to perform ...
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals ( NASDAQ:REGN )
LINKER-MM1 trial showed a 70% response rate, with 45% of patients achieving a complete response or better. Estimated duration of response reached 89% at 9 months, 72% at 12 months, with a median follow-up of 13 months. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% ...
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
Lynozyfic™ ( linvoseltamab-gcpt ) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
TARRYTOWN, N.Y., July 02, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has granted accelerated approval for Lynozyfic™ ( linvoseltamab-gcpt ) to treat adult patients with relapsed or refractory ( R/R ...
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, Regeneron Pharmaceuticals has a market capitalization of $56.34 billion.
Regeneron Pharmaceuticals Unusual Options Activity For July 01 - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 14 trades.
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
TARRYTOWN, N.Y., June 26, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open.
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., June 26, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open.
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? - Nektar Therapeutics ( NASDAQ:NKTR )
Rezpeg improves eczema symptoms by 53%-61% at 16 weeks vs. 31% for placebo. All dose levels met primary and secondary endpoints in Phase 2b trial. See how Matt Maley is positioning for global volatility, sector rotations, and macro shifts-live this Wednesday, June 25 at 6 PM ET.
